Thalassemia Treatment Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026

May 2018| TMR639A| Transparency

Report Highlights

Thalassemia Treatment Market - Overview

This report analyzes the current and future scenario of the global thalassemia treatment market. Large number of health care investors such as governments, social security funds, and insurance companies are struggling to meet the rising costs of medical treatments and research & development. Promising pipeline drugs and novel therapies, programs for increasing awareness about thalassemia, and rise in prevalence of thalassemia are the major drivers of the global thalassemia treatment market.

The global thalassemia treatment market report comprises an elaborate executive summary, which includes a snapshot that provides information about various segments of the market. It also provides information and data analysis of the global market with respect to the segments based on treatment type and region. A detailed qualitative analysis of drivers and restraints of the market and opportunities has been provided in the overview section. Additionally, the section comprises pipeline of thalassemia treatment by country/region, prevalent treatment regimens by country/region, and cost of treatment by region/country to understand the competitive landscape in the market. This section of the report also provides market attractiveness analysis by region and market share analysis by key players, thereby presenting a thorough analysis of the overall competitive scenario in the global thalassemia treatment market.

Based on treatment type, the global thalassemia treatment market has been segmented into blood transfusion, chelating therapy, bone marrow transplant, others (surgery, general medicines, etc.). These segments have been analyzed based on available approved treatment procedure, cost-effectiveness, and preference for treatment by physicians and patients. The market size and forecast for each of these segments have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year.

Geographically, the global thalassemia treatment market has been categorized into five major regions and the key countries in the respective region: North America (the U.S. and Canada), Europe (the U.K., Germany, Russia, France, Spain, Italy, and Rest of Europe), Asia Pacific (India, China, ASEAN countries, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (South Africa, GCC Countries, and Rest of Middle East & Africa). The market size and forecast for each of these regions and the mentioned countries have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year. The research study also covers the competitive scenario in these regions.

The report also profiles major players in the global thalassemia treatment market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major players profiled in this report include bluebird bio, Inc., Acceleron Pharma, Inc., Novartis AG, Celgene Corporation, Shire plc (Takeda Pharmaceuticals), Incyte Corporation, Kiadis Pharma, Gamida Cell, Bellicum Pharmaceuticals, and GlaxoSmithKline plc.

The global thalassemia treatment market has been segmented as given below:

Global Thalassemia Treatment Market, by Treatment Type
Blood Transfusion
Chelation Therapy
Bone Marrow Transplantation
Others

Global Thalassemia Treatment Market, by Region
North America
U.S.
Canada
Europe
U.K.
Germany
France
Italy
Spain
Rest of Europe
Asia Pacific
China
India
ASEAN Countries
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa
GCC Countries
South Africa
Rest of Middle East & Africa

  • Table 1 : Global Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
  • Table 2 : Global Thalassemia Treatment Market Value (US$ Mn) Forecast, by Region, 2016–2026
  • Table 3 : North America Thalassemia Treatment Market Value (US$ Mn) Forecast, by Country, 2016–2026
  • Table 4 : North America Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
  • Table 5 : U.S. Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
  • Table 6 : Canada Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
  • Table 7 : Europe Thalassemia Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
  • Table 8 : Europe Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
  • Table 9 : U.K. Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
  • Table 10 : Germany Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016-2026
  • Table 11 : France Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
  • Table 12 : Italy Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
  • Table 13 : Spain Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
  • Table 14 : Rest of Europe Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
  • Table 15 : Asia Pacific Thalassemia Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
  • Table 16 : Asia Pacific Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
  • Table 17 : India Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
  • Table 18 : China Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
  • Table 19 : ASEAN Countries Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
  • Table 20 : Rest of Asia Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
  • Table 21 : Latin America Thalassemia Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
  • Table 22 : Latin America Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
  • Table 23 : Brazil Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
  • Table 24 : Mexico Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
  • Table 25 : Rest of Latin America Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
  • Table 26 : Middle East & Africa Thalassemia Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
  • Table 27 : Middle East & Africa Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
  • Table 28 : South Africa Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
  • Table 29 : GCC Countries Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
  • Table 30 : Rest of Middle East & Africa Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
  • Figure 1 : Global Thalassemia Treatment Market Size (US$ Mn) Forecast, 2016–2026
  • Figure 2 : Global Thalassemia Treatment Market Value Share, by Region (2017)
  • Figure 3 : Global Thalassemia Treatment Market Value Share, by Treatment Type (2017)
  • Figure 4 : Global Thalassemia Treatment Market Value Share, by Treatment Type, 2018 and 2026
  • Figure 5 : Global Thalassemia Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Blood Transfusion, 2017–2026
  • Figure 6 : Global Thalassemia Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Chelating Therapy, 2017–2026
  • Figure 7 : Global Thalassemia Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Bone Marrow Transplant, 2017–2026
  • Figure 8 : Global Thalassemia Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Others, 2017–2026
  • Figure 9 : Global Thalassemia Treatment Market Attractiveness, by Treatment Type, 2018–2026
  • Figure 10 : Global Thalassemia Treatment Market Value Share, by Region, 2018 and 2026
  • Figure 11 : Global Thalassemia Treatment Market Attractiveness, by Region, 2018–2026
  • Figure 12 : North America Thalassemia Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2026
  • Figure 13 : North America Thalassemia Treatment Market Value Share, by Country, 2018–2026
  • Figure 14 : North America Thalassemia Treatment Market Attractiveness, by Country, 2018–2026
  • Figure 15 : North America Thalassemia Treatment Market Value Share, by Treatment Type, 2018 and 2026
  • Figure 16 : North America Thalassemia Treatment Market Attractiveness, by Treatment Type, 2018–2026
  • Figure 17 : Europe Thalassemia Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2026
  • Figure 18 : Europe Thalassemia Treatment Market Value Share, by Country/Sub-region, 2018–2026
  • Figure 19 : Europe Thalassemia Treatment Market Attractiveness, by Country/Sub-region, 2018–2026
  • Figure 20 : Europe Thalassemia Treatment Market Value Share, by Treatment Type, 2018 and 2026
  • Figure 21 : Europe Thalassemia Treatment Market Attractiveness, by Treatment Type, 2018–2026
  • Figure 22 : Asia Pacific Thalassemia Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2026
  • Figure 23 : Asia Pacific Thalassemia Treatment Market Value Share, by Country/Sub-region, 2018–2026
  • Figure 24 : Asia Pacific Thalassemia Treatment Market Attractiveness, by Country/Sub-region, 2018–2026
  • Figure 25 : Asia Pacific Thalassemia Treatment Market Value Share, by Treatment Type, 2018 and 2026
  • Figure 26 : Asia Pacific Thalassemia Treatment Market Attractiveness, by Treatment Type, 2018–2026
  • Figure 27 : Latin America Thalassemia Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2026
  • Figure 28 : Latin America Thalassemia Treatment Market Value Share, by Country/Sub-region, 2018–2026
  • Figure 29 : Latin America Thalassemia Treatment Market Attractiveness, by Country/Sub-region, 2018–2026
  • Figure 30 : Latin America Thalassemia Treatment Market Value Share, by Treatment Type, 2018 and 2026
  • Figure 31 : Latin America Thalassemia Treatment Market Attractiveness, by Treatment Type, 2018–2026
  • Figure 32 : Middle east & Africa Thalassemia Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2026
  • Figure 33 : Middle East & Africa Thalassemia Treatment Market Value Share, by Country/Sub-region, 2018–2026
  • Figure 34 : Middle East & Africa Thalassemia Treatment Market Attractiveness, by Country/Sub-region, 2018–2026
  • Figure 35 : Middle East & Africa Thalassemia Treatment Market Value Share, by Treatment Type , 2018 and 2026
  • Figure 36 : Middle East & Africa Thalassemia Treatment Market Attractiveness, by Treatment Type, 2018–2026
  • Figure 37 : Global Thalassemia Treatment Market Performance, by Company, 2017
  • Figure 38 : bluebird bio, Inc., Revenue (US$ Mn) & Y-o-Y Growth (%), 2014-2017
  • Figure 39 : bluebird bio, Inc., Research & Development (US$ Mn) – Company Level, 2014–2017
  • Figure 40 : bluebird bio, Inc., Breakdown of Revenue Generation (US$ Mn), by Collaboration, 2014-2017
  • Figure 41 : bluebird bio, Inc., Breakdown of R&D Cost to Company (%), by Products in Pipeline, 2017
  • Figure 42 : Acceleron Pharma, Inc., Revenue (US$ Mn) & Y-o-Y Growth (%), 2014-2017
  • Figure 43 : Acceleron Pharma, Inc., Research & Development (US$ Mn) – Company Level, 2014–2017
  • Figure 44 : Acceleron Pharma, Inc., Breakdown of Revenue Generation (US$ Mn), by Collaboration, 2014-2017
  • Figure 45 : Acceleron Pharma, Inc., Breakdown of R&D Cost to Company (%), by Products in Pipeline, 2017
  • Figure 46 : Novartis AG, Revenue (US$ Mn) & Y-o-Y Growth (%), 2014-2017
  • Figure 47 : Novartis AG, Research & Development (US$ Mn) and Marketing & Sales (US$ Mn)– Company Level, 2016–2017
  • Figure 48 : Novartis AG, Net Sales (%), by Oncology Business Units, 2017
  • Figure 49 : Novartis AG, Net Sales (%), by Business Segment, 2017
  • Figure 50 : Incyte Corporation, Revenue (US$ Mn) & Y-o-Y Growth (%), 2014-2017
  • Figure 51 : Incyte Corporation, Research & Development (US$ Mn) – Company Level, 2014–2017
  • Figure 52 : Incyte Corporation, Breakdown of Revenue Generation (US$ Mn), by Royalties, 2014-2017
  • Figure 53 : Incyte Corporation, Breakdown of Sales (%), by Products, 2017
  • Figure 54 : Kiadis Pharma, Revenue (US$ Mn) & Y-o-Y Growth (%), 2014-2017
  • Figure 55 : Kiadis Pharma, Research & Development (US$ Mn) – Company Level, 2014–2017
  • Figure 56 : Kiadis Pharma, Breakdown of Revenue Generation (US$ Mn), by Operating and Investing Activities, 2016-2017
  • Figure 57 : Kiadis Pharma, Breakdown of Operating Cost to Company (%), 2016 and 2017
  • Figure 58 : Shire plc, Revenue (US$ Mn) & Y-o-Y Growth (%), 2014-2017
  • Figure 59 : Shire plc, Research & Development (US$ Mn) – Company Level, 2014–2017
  • Figure 60 : Shire plc, Breakdown of Revenue Generation (%), by Region/Country, 2017
  • Figure 61 : Shire plc, Breakdown of Product Sales to Company (%), 2017
  • Figure 62 : Celgene Corporation, Revenue (US$ Mn) & Y-o-Y Growth (%), 2014-2017
  • Figure 63 : Celgene Corporation, Research & Development (US$ Mn) – Company Level, 2014–2017
  • Figure 64 : Celgene Corporation, Breakdown of Revenue Generation (US$ Mn), by Region, 2015-2017
  • Figure 65 : Celgene Corporation, Net Sales(%), by Products, 2017
  • Figure 66 : Bellicum Pharmaceuticals, Revenue (US$ Mn) & Y-o-Y Growth (%), 2014-2017
  • Figure 67 : Bellicum Pharmaceuticals, Research & Development (US$ Mn) – Company Level, 2014–2017
  • Figure 68 : Bellicum Pharmaceuticals, Breakdown of Revenue Expenses (US$ Mn), by Collaboration and License Agreement, 2014-2017
  • Figure 69 : Bellicum Pharmaceuticals, Breakdown of R&D Cost to Company (%), by Products in Pipeline, 2017
  • Figure 70 : GlaxoSmithKline Plc., Revenue (US$ Mn) & Y-o-Y Growth (%), 2014-2017
  • Figure 71 : GlaxoSmithKline Plc., Research & Development (US$ Mn) – Company Level, 2014–2017
  • Figure 72 : GlaxoSmithKline Plc., Breakdown of Revenue Generation (US$ Mn), by Products, 2014-2017
  • Figure 73 : GlaxoSmithKline Plc., Breakdown of Sales(%), by Region, 2017

Leaders in analytics, research and advisory services for Fortune 500 companies, scores of high potential startups, and financial institutions. Our success stories have proven why we are a prominent provider of a cutting-edge syndicated and customized research services. Leverage the best of our seasoned research analysts who had a keen interest and enviable expertise of almost 4 million hours in global, regional, and local market intelligence.

Why BCC Research?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries
CUSTOM RESEARCH

Need a custom data table, graph or complete report? Tell us more.

Contact Us
Share This Report